SCHEMBL1487464

SCHEMBL1487464

Cc1ccnn1C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22245517 0.81
SCHEMBL11343055 0.81
SCHEMBL23791343 0.81
SCHEMBL31265781 0.81 ALDH1A1 (0.55)
SCHEMBL17551252 0.78
SCHEMBL12915265 0.78 ALDH1A1 (0.52)
SCHEMBL22143665 0.78 ALDH1A1 (0.52)
SCHEMBL12128212 0.78 ALDH1A1 (0.52)
SCHEMBL22143779 0.78 ALDH1A1 (0.56)
SCHEMBL11480863 0.78 ALDH1A1 (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111670186-B Pyrazolopyridine-diamides, their use as pesticides and process for their preparation PI工业有限公司 2023-10-17 CN claimed
US-20240239757-A1 PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-07-18 US disclosed
WO-2024151547-A1 TARGETED DEGRADATION OF VAV1 MONTE ROSA THERAPEUTICS, INC. (US) 2024-07-18 WO disclosed
US-20240239757-A1 PHTHALAZINONE DERIVATES AS NLRP3 INFLAMMASOME INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2024-07-18 US disclosed
US-20240226113-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2024-07-11 US disclosed
US-20240226113-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2024-07-11 US disclosed
US-12024614-B2 Rubber compounding ingredient and rubber composition SHIN-ETSU CHEMICAL CO., LTD. (JP) 2024-07-02 US disclosed
WO-2024026500-A2 INHIBITORS OF PDE11A4 AND METHODS OF USING SAME UNIVERSITY OF MARYLAND, BALTIMORE (US) 2024-02-01 WO disclosed
US-20230373963-A1 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF BEIGENE, LTD. (KY) 2023-11-23 US disclosed
US-11820756-B2 Bradykinin B2 receptor antagonists Pharvaris Netherlands B.V. (NL) 2023-11-21 US disclosed
US-7279474-B2 Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) GLAXO GROUP LIMITED (GB) 2007-10-09 US disclosed
CN-1238363-C Glucopyranosyloxypyrazole derivatives and use thereof in medicines KISSEI PHARMACEUTICAL (JP) 2006-01-25 CN disclosed
US-20050153059-A1 Partial plating method, partially-plated resin base, method for manufacturing multilayered circuit board ZEON CORPORATION (JP) 2005-07-14 US disclosed
CN-1639384-A Partial plating method, partially-plated resin base, method for manufacturing multilayer circuit board ZEON CORP (JP) 2005-07-13 CN disclosed
US-20040237295-A1 Multilayer circuit board and resin base material, and its production method ZEON CORPORATION (JP) 2004-12-02 US disclosed
CN-1552174-A Mulitilayer circuit board, resin base material, and its production method �ձ�������ʽ���� 2004-12-01 CN disclosed
CN-1492873-A Glucopyranosyloxypyrazole derivatives and their use in medicaments ����ҩƷ��ҵ��ʽ���� 2004-04-28 CN disclosed
EP-0628563-B1 Process for the preparation of N-substituted pyrazoles BASF AG (DE) 1999-03-03 EP disclosed
US-5468871-A Catalytic N-alkylation BASF AKTIENGESELLSCHAFT (DE) 1995-11-21 US disclosed
EP-0628563-A1 Process for the preparation of N-substituted pyrazoles BASF Aktiengesellschaft (DE) 1994-12-14 EP disclosed